Abstract Background and Objective Low-dose acetylsalicylic acid (ASA, aspirin) is a well-
known and frequently studied drug for primary and secondary prevention of disease due to …

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) can induce inflammatory
and thrombotic complications of pulmonary district (interstitial pneumonia), sometimes …

Introduction: Thromboembolic events are one of the important complications in COVID-19
patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting …

Background Mortality in critically ill COVID-19 patients remains high. Although randomized
controlled trials must continue to definitively evaluate treatments, further hypothesis …

Background Thrombotic events are common in critically ill patients with COVID-19 and have
been linked with COVID-19-induced hyperinflammatory state. In addition to anticoagulant …

Coronavirus disease 2019 (COVID-19) is a new viral disease complicating with acute
thrombophylic conditions, probably also via an inflammatory burden. Anticoagulants are …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …

A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with
CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of …

Introduction The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …

Abstract Background Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2)
infection is associated with hypercoagulability caused by direct invasion of endothelial cells …